MedPage Today on MSN6d
FDA Approves Ocular Implant for Vision-Threatening MacTel
A rare, progressive neurodegenerative disease associated with loss of macular photoreceptors in the retinas, MacTel type 2 ...
Fierce Pharma3d
Neurotech nabs FDA approval to treat rare eye disorder with cell therapy implant Encelto
With a U.S. green light for its encapsulated cell therapy technology in the bag, privately held biotech Neurotech ...
MedCity News5d
Gene Therapy in an Implant: Neurotech Lands First FDA Approval in Rare Vision Disorder
Neurotech Pharmaceuticals’ gene therapy comes in a surgical implant, and it’s now the first FDA-approved treatment for a rare vision-loss disorder. The approval handed out on March 5 covers ...
Ophthalmology Times7d
FDA approves revakinagene taroretcel-lwey (ENCELTO) for macular telangiectasia type 2
Phase 3 trials demonstrated ENCELTO significantly slowed macular photoreceptor loss in MacTel patients over 24 months.
New Jersey Business Magazine7d
Vision Center Becomes First in NJ to Offer FDA-Approved Valeda Light Therapy
The Laser Vision Correction Center of New Jersey is the first practice in New Jersey to offer the Valeda Light Delivery ...
MedPage Today7d
FDA Approves Ocular Implant for Vision-Threatening MacTel
"Now with an FDA-approved treatment ... allowing them the opportunity to preserve more functional vision over time." According to the prescribing information, common adverse events in the studies ...
MPR7d
FDA Approves Encelto for Macular Telangiectasia Type 2
MacTel is a rare, progressive eye disease that affects the macula and causes a gradual deterioration in central vision.